![Ideanomics (delisted)](/common/images/company/N_SSC.png)
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis PR Newswire WALTHAM, Mass., July 9, 2024 -- Exceeded enrollment target due...
Q32 Bio Joins Russell 3000® Index PR Newswire WALTHAM, Mass., July 1, 2024 WALTHAM, Mass., July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology...
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., May 9, 2024 -- Completed enrollment in bempikibart alopecia areata (AA) Phase 2...
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer PR Newswire WALTHAM, Mass., April 3, 2024 WALTHAM, Mass., April 3, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.